Today's Research Daily features new research reports on 12 major stocks, including Eli Lilly and Company (LLY), CVS Health Corporation (CVS), and Target Corporation (TGT)
Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Two dividend stocks that have been beating the markets by wide margins this year include Eli Lilly (NYSE: LLY) and ExxonMobil (NYSE: XOM). Drugmaker Eli Lilly has seen its share price rise 9% thus far in 2022. This month, Eli Lilly released its second-quarter numbers, which showed sales of $6.5 billion for the period ended June 30, down 4% year over year; however, this falls to a decline of just 1% when factoring out the impact of foreign currency exchange.